Hormonal Therapies for Acne: A Comprehensive Update for Dermatologists

    January 2025 in “ Dermatology and Therapy ”
    Courtney Smith, Emily Gosnell, Turkan Banu Karatas … Howa Yeung
    Studysummary This review updates dermatologists on both FDA-approved and off-label hormonal therapies, including combined oral contraceptives, clascoterone, and spironolactone, used for acne treatment, providing insights into emerging approaches for managing the condition.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on link.springer.com →
    Discuss this study in the Community →

    Research cited in this study 9

    1. Guidelines of Care for the Management of Acne Vulgaris Journal of the American Academy of Dermatology · 2024
    2. Correlations Between Hormonal Intrauterine Devices and Androgenic Skin Conditions: A Retrospective Cohort Study Journal of The American Academy of Dermatology · 2022
    3. Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-Analysis JAMA Dermatology · 2022
    4. Trends in the Prescribing Pattern of Spironolactone for Acne and Hidradenitis Suppurativa in Adolescents Journal of The American Academy of Dermatology · 2021
    5. Dual Effects of 5α-Reductase Inhibitor Dutasteride on Androgenetic Alopecia and Acne Vulgaris Dermatologica Sinica · 2019
    6. A Review of Hormone-Based Therapies to Treat Adult Acne Vulgaris in Women International Journal of Women's Dermatology · 2017
    7. Spironolactone for the Treatment of Acne: A 4-Year Retrospective Study Dermatology · 2017
    8. Adverse Effects and Safety of 5-Alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review PubMed · 2016
    9. Efficacy of an Oral Contraceptive Containing EE 0.03 mg and CMA 2 mg (Belara) in Moderate Acne Resolution: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial Contraception · 2009